Viking Therapeutics(NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market.

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market.

Is this a good time to buy shares of Viking Therapeutics, or could more of a decline be coming this year? The case for buying shares of Viking stock today Making a bullish case for Viking ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has ...

Date and time: recurring weekly on Wednesdays from 8 a.m. to 11 p.m. Come Downtown every Wednesday with your Western Student, Staff, or Faculty ID to score deals and discounts all day long at 60 ...

HIMS after being taken off the drug shortage list. However, there has been major buzz about a new GLP treatment from Viking Therapeutics Inc. VKTX that threatens to disrupt the GLP-1 duopoly.

However, there has been major buzz about a new GLP treatment from Viking Therapeutics Inc. (NASDAQ: VKTX) that threatens to disrupt the GLP-1 duopoly. Why VK2735’s Dual GLP-1/GIP Action Could ...

Viking Therapeutics experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 program targeting ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In somewhat of a surprise move, Viking Therapeutics just announced a production deal with CordenPharma, a privately held Swiss company. The move supports the commercial launch of a drug just now ...

Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.